Lee M Hampton

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. doi request reprint Cough and cold medication adverse events after market withdrawal and labeling revision
    Lee M Hampton
    MSc, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A 24, Atlanta, GA 30329
    Pediatrics 132:1047-54. 2013
  2. doi request reprint Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines
    Lee M Hampton
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA
    J Infect Dis 205:401-11. 2012
  3. pmc Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness
    Lee M Hampton
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Bull World Health Organ 90:568-77. 2012
  4. doi request reprint Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine
    Charles Stoecker
    National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA
    Pediatrics 132:e324-32. 2013
  5. doi request reprint Efficacy of flow restrictors in limiting access of liquid medications by young children
    Maribeth C Lovegrove
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA
    J Pediatr 163:1134-9.e1. 2013
  6. doi request reprint 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series
    Charles Stoecker
    National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Vaccine 30:6256-62. 2012

Collaborators

Detail Information

Publications6

  1. doi request reprint Cough and cold medication adverse events after market withdrawal and labeling revision
    Lee M Hampton
    MSc, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A 24, Atlanta, GA 30329
    Pediatrics 132:1047-54. 2013
    ..We determined whether emergency department (ED) visits for CCM adverse drug events (ADEs) declined after these interventions...
  2. doi request reprint Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines
    Lee M Hampton
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA
    J Infect Dis 205:401-11. 2012
    ....
  3. pmc Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness
    Lee M Hampton
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Bull World Health Organ 90:568-77. 2012
    ....
  4. doi request reprint Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine
    Charles Stoecker
    National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, USA
    Pediatrics 132:e324-32. 2013
    ..We examined the cost-effectiveness of switching from 4 total doses to 3 total doses by removing the third dose in the primary series in the United States...
  5. doi request reprint Efficacy of flow restrictors in limiting access of liquid medications by young children
    Maribeth C Lovegrove
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA
    J Pediatr 163:1134-9.e1. 2013
    ..To assess whether adding flow restrictors (FRs) to liquid medicine bottles can provide additional protection against unsupervised medication ingestions by young children, even when the child-resistant closure is not fully secured...
  6. doi request reprint 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series
    Charles Stoecker
    National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Vaccine 30:6256-62. 2012
    ..Using data from the United States after the 2000 introduction of PCV7, we compared the effectiveness of a 2- versus a 3-dose primary series against acute otitis media (AOM)...